|
Neonatal Intensive Care Drug Manual
|
| bet | 207/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Flecainide
Revision Date : 12-01-2021
|
Approved : TC, KOH
|
Alert
|
Use in consultation with a Paediatric Cardiologist.
Contraindicated in infants with reduced myocardial contractility.
Use caution in patients with congenital heart disease—increased potential for pro-arrhythmic effects.
Intravenous flecainide needs close cardiorespiratory monitoring
|
Indication
|
Treatment of paroxysmal supraventricular tachycardia, paroxysmal atrial fibrillation/flutter and life- threatening ventricular dysrhythmias as a second-line agent where tachycardia has been resistant to first-line agents.
|
Action
|
Decreases intracardiac conduction for all parts of the heart, with the greatest effect in the His-Purkinje system. It acts by blocking fast sodium channels. As a type Ic agent, it slows cardiac conduction and decreases contractility.
|
Drug type
|
Type Ic antiarrhythmic agent.
|
Trade name
|
Flecainide Sandoz Tablets; Flecatab Tablets; Tambocor solution for injection, Tambocor Tablets
|
|
|
| |
